Suchergebnisse - "Janjigian, Yelena Y"

PubPharm (19)

1

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma : interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

enthalten in: Lancet (London, England) | 2023

von Janjigian, Y. | Kawazoe, A. | Bai, Y. | +18

CommentIn: Lancet. 2023 Dec 9;402(10418):2168-2170. - PMID 37871605

2

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Maron, S. | Chatila, W. | Walch, H. | +31

3

Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET : A Pilot Study

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2023

von Lumish, M. | Maron, S. | Paroder, V. | +9

4

HER2 Targeting in Esophagogastric Cancer : Redefining the Landscape and Breaking Barriers

enthalten in: Journal of the National Comprehensive Cancer Network : JNCCN | 2023

von Cytryn, S. | Janjigian, Y.

5

Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer

enthalten in: Nature communications | 2022

von Pereira, P. | Mandleywala, K. | Monette, S. | +10

6

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

enthalten in: Nature | 2021

von Janjigian, Y. | Kawazoe, A. | Yañez, P. | +17

CommentIn: Nature. 2021 Dec;600(7890):608-609. - PMID 34912062

7

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer : KEYNOTE-811

enthalten in: Future oncology (London, England) | 2021

von Chung, H. | Bang, Y. | S Fuchs, C. | +11

8

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer : an open-label, single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2020

von Janjigian, Y. | Maron, S. | Chatila, W. | +22

CommentIn: Lancet Oncol. 2020 Jun;21(6):741-743. - PMID 32437663

9

Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2019

von Pereira, P. | Mandleywala, K. | Ragupathi, A. | +4

10

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2019

von Mondaca, S. | Margolis, M. | Sanchez-Vega, F. | +19